Extracorporeal Carbon Dioxide Removal (ECCO2R) Devices Market Size, Share and Global Trend By Product (Extracorporeal CO2 Machines, Disposables), Application (Chronic Pulmonary Obstructive Disease, Acute Respiratory Distress Syndrome, Bridge to Transplant), Access (Venovenous Access, Arteriovenous Access), End Users (Clinics, Ambulatory Surgery Centres, Hospitals) and Regional Forecast, 2024-2032

According to The Intensive Care Society, extracorporeal CO2 removal device is used to expedite artificial respiration for patients suffering from acute respiratory failure. Constantly increasing prevalence of acute respiratory failure, respiratory distress syndrome, severe asthma and chronic obstructive pulmonary disease combined with the ability of extracorporeal CO2 removal device to provide robust respiratory support is propelling the adoption of these devices. In 2017, ALung Technologies closed series C funds of US$ 36 Mn with the aim to conduct US based pivotal trail for FDA approval of Hemolung Respiratory Assist System (RAS), which removes carbon dioxide from the lungs with the help of respiratory dialysis.

An aging population, the growing prevalence of acute respiratory distress and rising incidence of the chronic pulmonary obstructive disease are prominently expected to drive the growth of the global extracorporeal CO2 removal devices market by 2026. According to data published by the World Health Organization (WHO), in 2016, 251 million people were affected by chronic pulmonary obstructive disorder worldwide. Moreover, according to projections given by the World Health Organization (WHO), the prevalence of the chronic pulmonary obstructive disease is expected to grow due to higher smoking prevalence and aging population in the forecast period. Combined with this, clinical benefits offered by extracorporeal CO2 removal devices such as robust lung support, vitalizing blood flow, and efficient gas exchange are expected to offer higher potential for growth of the global extracorporeal CO2 removal devices market during the forecast period.

Increased risks of side effects of applications of extracorporeal CO2 removal device such as thrombosis due to minimal blood flow through circuit and risk of hypoxemia are deterring the growth of the global extracorporeal CO2 removal devices market.

Key Players Covered:

Some of the major companies that are present in the global extracorporeal carbon dioxide removal (ECCO2R) devices market are ALung Technologies, Inc., Getinge AB., Medtronic, ESTOR S.P.A, XENIOS AG, MEDICA S.p.A. and other players.

SEGMENTATION

Among the products, disposables accounted for the largest proportion of the global extracorporeal carbon dioxide removal (ECCO2R) market in 2018, due to increasing adoption of ECCO2 devices, supported by higher replacement rate of disposables.

Key Insights

• Epidemiology of Acute Respiratory Distress Syndrome - For Key Countries, 2018


• Key Mergers and Acquisitions

Regional Analysis:

The global extracorporeal carbon dioxide removal (ECCO2R) devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global extracorporeal CO2 removal devices market owing to the rise in prevalence of acute asthma, exponentially increasing air pollution due to the rapid pace of industrialization and adoption of a sedentary lifestyle. Moreover, growth in certain conditions such as growth in smoking, an aging population, and adoption of sedentary lifestyle is expected to rise the prevalence of respiratory distress conditions, resulting into increased adoption of extracorporeal CO2 removal devices. The Asia Pacific and Middle East and Africa also hold huge potential for growth of the global extracorporeal CO2 removal devices owing to rising prevalence of respiratory distress conditions. Also, growing healthcare infrastructure and rise in per capita expenditure is projected to accelerate the growth of the global extracorporeal CO2 removal devices market in these particular regions

Key Industry Developments

• In February 2013, Hemolung Respiratory Assist System (RAS) which was manufactured by ALung Technologies got CE approval and initially it was available for hospitals under ALung’s Hemolung Reference Centre Program.


• In September 2017, Hemolung Respiratory Assist System (RAS) got IDE (Investigational Device Exemption) approval for conducting VENT-AVOID trials of the system.


• In December 2018, ALung Technologies announced the significant progress in clinical trial programs regarding Hemolung Respiratory Assist System (RAS), a catheter that plays major role in extracorporeal Co2 removal process.